Matthew Judson is a research associate in the UNC Neuroscience Center at the University of North Carolina at Chapel Hill.
![Headshot of Matthew Judson](https://www.thetransmitter.org/wp-content/uploads/2018/10/IMG_5141_crop-cc.jpg)
Matthew Judson
Research associate
University of North Carolina at Chapel Hill
From this contributor
Angelman syndrome: Bellwether for genetic therapy in autism
It is not a matter of whether there will be clinical trials of genetic therapy for Angelman syndrome, but when.
![An illustration shows a mosaic-like view of viruses delivering genes to the brain.](https://www.thetransmitter.org/wp-content/uploads/2018/10/20181016-Philpot844-cc.jpg)
Angelman syndrome: Bellwether for genetic therapy in autism
Insights for autism from Angelman syndrome
Deletions or duplications of the UBE3A gene lead to both Angelman syndrome and some cases of autism, respectively. Studying the effects of altered gene dosage in this region will provide insights into brain defects and suggest targets for therapies for both disorders, says expert Benjamin Philpot.
![Neurons](https://www.thetransmitter.org/wp-content/uploads/2011/07/Neurons844.jpg)
Insights for autism from Angelman syndrome
Explore more from The Transmitter
Cell population in brainstem coordinates cough, new study shows
The work also adds to a growing body of evidence showing that mice, and their genetic toolbox, can be used to study cough.
![](https://www.thetransmitter.org/wp-content/uploads/2024/09/1200_coughingmice-1024x720.webp)
Cell population in brainstem coordinates cough, new study shows
The work also adds to a growing body of evidence showing that mice, and their genetic toolbox, can be used to study cough.
In updated U.S. autism bill, Congress calls for funding boost, expanded scope
The current Autism CARES Act sunsets in late September.
![Capitol building](https://www.thetransmitter.org/wp-content/uploads/2024/09/capitolhill-1200-1024x692.webp)
In updated U.S. autism bill, Congress calls for funding boost, expanded scope
The current Autism CARES Act sunsets in late September.
Ketamine targets lateral habenula, setting off cascade of antidepressant effects
The drug’s affinity for overactive cells in the “anti-reward” region may help explain its rapid and long-lasting results.
![Illustration of ketamine blocking open ion channels in active NMDA receptors, quieting the cells and disrupting downstream signaling involved in depression.](https://www.thetransmitter.org/wp-content/uploads/2024/09/1200-ketamine-receptor-transmitter-neuroscience-1024x683.webp)
Ketamine targets lateral habenula, setting off cascade of antidepressant effects
The drug’s affinity for overactive cells in the “anti-reward” region may help explain its rapid and long-lasting results.